Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : IAVI
Deal Size : Inapplicable
Deal Type : Inapplicable
IAVI, Biofabri Start IMAGINE Trial for Tuberculosis Vaccine Candidate MTBVAC
Details : MTBVAC is a live-attenuated vaccine candidate, derived from a human isolate of Mycobacterium tuberculosis. It is being evaluated to prevent active TB lung disease in adolescents and adults.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Inapplicable
February 26, 2025
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : IAVI
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : IAVI
Deal Size : Undisclosed
Deal Type : Agreement
Zendal and IAVI Announce Expanded Agreement to Partner on Development of TB Vaccine Candidate MTBVAC
Details : Under the agreement, IAVI is supporting development, global regulatory strategy, resource mobilization, and access planning for the adolescent/adult tuberculosis (TB) vaccine candidate MTBVAC.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Undisclosed
May 17, 2023
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : IAVI
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The final results of APLICOV-PC study (Phase I-II), demonstrate the safety of Aplidin (plitidepsin) use in patients with COVID-19 and postulate a positive therapeutic impact on the evolution of the disease.
Product Name : Aplidin
Product Type : Peptide
Upfront Cash : Inapplicable
November 01, 2022
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,BCG Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Bharat Biotech
Deal Size : Undisclosed
Deal Type : Partnership
Details : This agreement between BHARAT BIOTECH and BIOFABRI would guarantee the worldwide production and the supply of the future vaccine, MTBVAC in more than 70 countries with a high TB incidence, such as India, country with the highest TB burden in the world, w...
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Undisclosed
March 16, 2022
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated,BCG Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Bharat Biotech
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : IAVI
Deal Size : Undisclosed
Deal Type : Partnership
Details : MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.
Product Name : MTBVAC
Product Type : Vaccine
Upfront Cash : Undisclosed
July 14, 2021
Lead Product(s) : Mycobacterium Tuberculosis Vaccine, Live Attenuated
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : IAVI
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Spain's PharmaMar Says Covid-19 Treatment Drug Shows Clinical Efficacy in Trials
Details : The APLICOV-PC study evaluated three cohorts of hospitalized patients with mild, moderate or severe disease, with three different dose levels of plitidepsin (1.5mg - 2.0mg - 2.5mg), administered on three consecutive days.
Product Name : Aplidin
Product Type : Peptide
Upfront Cash : Inapplicable
May 26, 2021
Lead Product(s) : Plitidepsin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyperimmune Immunoglobulin,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Phase 3 Inpatient Treatment with Anti-Coronavirus Immunoglobulin (hIVIG) clinical trial, also known as INSIGHT-013 did not meet its primary endpoints with statistically significant results.
Product Name : hIVIG
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
February 04, 2021
Lead Product(s) : Hyperimmune Immunoglobulin,Remdesivir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : National Institutes of Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Hyperimmune Globulin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Grifols' anti-SARS-CoV-2 Hyperimmune Globulin Begins Clinical Trial in Patients with COVID-19
Details : First international multicenter clinical trial of an anti-SARS-CoV-2 hyperimmune globulin and will include 500 hospitalized adults with COVID-19 in up to 58 hospitals in 18 countries. The therapy comes from the convalescent plasma of healthy people who h...
Product Name : ITAC
Product Type : Protein
Upfront Cash : Inapplicable
September 10, 2020
Lead Product(s) : Hyperimmune Globulin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : As part of the agreement, ROVI will provide vial filling and packaging capacity by procuring a new production line and equipment for compounding, filling, automatic visual inspection and labeling to support production of hundreds of millions of doses of ...
Product Name : mRNA-1273
Product Type : Vaccine
Upfront Cash : Undisclosed
September 07, 2020
Lead Product(s) : TAK-919
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Moderna Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration